Scintigraphic elvaluation of liver metastases from thyroid carcinoma.
(65/993)
Thirty-one patients with carcinoma of the thyroid were evaluated using 131-I scan of the torso including the area of the liver. Focal areas of 131I uptake were found in the liver in two patients with follicular thyroid carcinoma. Both patients showed associated abnormalities on 99m-Tc-sulfur colloid liver scans. The remaining 29 patients showed either no uptake or a normal diffuse pattern of 131-I uptake in liver. Careful evaluation of the liver is recommended on the radioiodine body scan for metastases in patients with thyroid carcinoma. (+info)
The effect of surface coverage and conformation of poly(ethylene oxide) (PEO) chains of poloxamer 407 on the biological fate of model colloidal drug carriers.
(66/993)
Poloxamer 407 was adsorbed onto the surface of model colloidal drug carriers, polystyrene nanoparticles of 40, 70 and 137 nm in diameter, and the effect of the degree of surface coverage and the conformation of the poly(ethylene oxide) (PEO) chains on biological fate was studied. The relationship between the physicochemical and the biological properties of the nanoparticle systems was also investigated. The adsorbed layer of poloxamer 407 was characterised in terms of percentage surface coverage, thickness of the adsorbed layer and average surface area per PEO chain. Computer modelling of the adsorbed layer was performed (applying the self-consistent field technique), to obtain the structural information of the PEO chains in the layer. The in vitro interaction of the nanoparticles with different degrees of poloxamer 407 surface coverage with serum components and the in vivo biodistribution in the rat model were assessed. The results demonstrated that an increase in the surface coverage with poloxamer 407 resulted in an increased volume fraction of the PEO in the adsorbed layer, further extension of the PEO chains from the surface and closer packing of the chains at the surface. With regard to the interaction with the serum components, an increased surface coverage resulted in a reduction of the amount of serum proteins adsorbed, and, importantly, affected the type of proteins adsorbed. High molecular weight proteins were not adsorbed onto the nanoparticles with a surface coverage above approx. 25%. Following the intravenous administration to rats, even the nanoparticles with the lowest degree of surface coverage (approx. 5%) showed improved circulation profiles relative to the uncoated nanoparticles. The effect was more pronounced for the 40 nm nanoparticles. A further increase in the surface coverage to approx. 25% resulted in a significant increase in circulation time, as compared to uncoated and 5% coated systems, for all sizes of nanoparticles. Importantly, it was found that a long in vivo blood circulation time could be achieved for nanoparticles with a relatively low degree of surface coverage with PEO chains. (+info)
The mechanism of oxidation-induced low-density lipoprotein aggregation: an analogy to colloidal aggregation and beyond?
(67/993)
Atherosclerosis is a disease initiated by lipoprotein aggregation and deposition in artery walls. In this study, the de novo low-density lipoprotein aggregation process was examined. Nine major intermediates were identified in two stages of the aggregation process. In the aggregation stage, low-density lipoprotein molecules aggregate and form nucleation units. The nucleation units chain together and form linear aggregates. The linear aggregates branch and interact with one another, forming fractals. In the fusion stage, spatially adjacent nucleation units in the fractal fuse into curved membrane surfaces, which, in turn, fuse into multilamellar or unilamellar vesicles. Alternatively, some adjacent nucleation units in the fractals assemble in a straight line and form rods. Subsequently, the rods flatten out into rough and then into smooth ribbons. Occasionally, tubular membrane vesicles are formed from the fractals. The aggregation stage seems to be analogous to colloidal aggregation and amyloid fiber formation. The fusion stage seems to be characteristic of the lipid-rich lipoproteins and is beyond colloidal aggregation and amyloid fiber formation. (+info)
In vivo distribution of vesicles loaded with radiopharmaceuticals: a study of different routes of administration.
(68/993)
The in vivo distribution of vesicles containing radiopharmaceuticals in their cavities has been studied using three routes of administration: intravenous, subcutaneous, and intraperitoneal. The in vivo distribution in mice was determined by dissection of the animals and calculation of radioactivity in the organs. In rats the in vivo distribution was assessed by scintigraphy using a scintillation camera-digital computer unit. After intravenous injection of vesicles, radioactivity is concentrated to some extent in the liver and spleen but the pattern of distribution is different from that of the corresponding free radiopharmaceutical or radiocolloid made of the corresponding radionuclide. The permeability of the vesicular membrane to contained radiopharmaceutical has been shown to vary according to the chemical composition of the vesicles. Vesicles can be used to introduce materials in vivo and the potential exists for their specific targeting by coupling other molecules to their surfaces. (+info)
Liver scan showing intense lung uptake in neoplasia and infection.
(69/993)
Two cases of intense lung activity uptake during routine liver imaging are presented. One patient died 6 days after uptake was seen, and had Kupffer cell tumor, or liver angiosarcoma, at autopsy. The second patient with an acute infection superimposed on alcholic hepatitis showed intense lung uptake on the tenth day of a sustained course of very high fever. A repeat liver scan after the patient became afebrile showed no lung uptake. (+info)
Lipid specificity of beta-hydroxybutyrate dehydrogenase activation.
(70/993)
Beef heart mitochondrial beta-hydroxybutyrate dehydrogenase forms a catalytically active complex with lecithin and is inactive in the absence of lecithin. The specificity of the activation process was probed by studying the interaction of the enzyme with phospholipids and other compounds. The compounds were tested for their ability to form active complexes with the enzyme, for the stability of the complex formed, and for the correlation between the activator concentration and the level activation. The phospholipids tested were synthetic lecithins varying in the length (C2 to C18) and degree of unsaturation of the aliphatic chains and in the stereochemistry and type of linkage from the aliphatic chain to the glycerol moiety, synthetic and egg yolk lysolecithins, stearylphosphorylcholine, egg yolk phosphatidylethanolamine, egg yolk phosphatidyl-O-serine, and synthetic cardiolipins. Lecithins, lysolecithins, and stearylphosphoryl-choline form active complexes with the enzyme; the L-alpha-diC4:0 is the smallest lecithin forming an active complex and L-alpha-C12:0 is the smallest lysolecithin. Glycerophosphorycholine, mytistoylcholine, N-trimethyl-n-dodecylamine, decamethonium, sodium dodecyl sulfate, Triton X-100, and Lubrol do not activate the enzyme. A hydrophobic chain followed sequentially by a negative and a positive charge, as in stearylphosphorylcholine, is the minimal structural requirement of an activator. However, the stability of the enzyme-activator complex depends strongly on the aggregation state of the activators, complexes of appreciable stability being formed only with those phospholipids which exist in bilayer membrane-like structures. Thus, lecithins with long aliphatic chains (C9 to C18) form active and stable complexes with the enzyme. The maximal activity and the strength of the lipid-protein interactions depend on the nature of the aliphatic chains of the lipids. Lecithins with saturated and unsaturated fatty acid chains activate the enzyme, but the latter form somewhat more stable complexes. The enzyme-activator interactions in the bilayers can be qualitatively understood in terms of competition between lipid-lipid and lipid-protein interactions: the strength of the interaction between the protein and phosphatidylcholines decreases as the crystalline to amorphous phase transition temperature, which is a measure of the strength of lipid-lipid interactions, increases... (+info)
In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel.
(71/993)
Paclitaxel (Taxol), a diterpenoid isolated from Taxus brevifolia, is effective against several murine tumors, and is one of the most exciting anticancer molecules currently available. Due to its low solubility in water, it is clinically administered with polyethoxylated castor oil (Cremophor EL), which causes serious side effects. Inclusion of paclitaxel in solid lipid nanoparticles (SLNs) has proved to be a good approach to eliminate the need for Cremophor EL and improve the drug's antitumor efficacy. This paper describes the development of two types of long-circulating SLNs as colloidal carriers for paclitaxel. SLNs are constituted mainly of bioacceptable and biodegradable lipids. In vitro release kinetics showed that the release was very slow, the release of paclitaxel from F68-SLN is linear, and the release of paclitaxel from Brij78-SLN followed the Weibull equation. Pharmacokinetics was evaluated in KM mice after injection of paclitaxel formulated in Cremophor EL or in Brij78-SLN and F68-SLN. Encapsulation of paclitaxel in both SLNs produced marked differences compared with the free drug pharmacokinetics. F68-SLN and Brij78-SLN are long-circulating (t 1/2 beta, 10.06 and 4.88 h, respectively) compared with paclitaxel injection (t 1/2 beta, 1.36 h). (+info)
Plasma colloid osmotic pressure in healthy infants.
(72/993)
BACKGROUND: The plasma colloid osmotic pressure (COP) plays a major role in transcapillary fluid balance. There is no information on plasma COP of healthy infants beyond the first post-natal week. The normal COP in healthy adult subjects (25 mmHg) is currently also applied as a reference value for healthy infants. This study was designed to test whether plasma COP values in healthy infants are the same as those in normal adults. METHODS: Plasma COP was measured in 37 male and female healthy infants from 1 to 11 months old. For this purpose, 1 ml blood was collected during the patient's regularly scheduled visit if the patient required any type of blood test for routine laboratory analyses. RESULTS: Plasma COP levels correlated slightly with increasing age from 1 to 9 months old (linear regression analysis; r2 = 0.1, P < 0.049). We found no correlation between plasma COP and body weight at the same age (r2 = 0.05, P = 0.155). The mean and standard deviation of COP in all infants was 25.1 +/- 2.6 mmHg, which is almost identical to an average COP of 25 mmHg in healthy adult subjects. Arbitrary division of the infants into three different age groups (1-3 months [n = 11], 5-8 months [n = 13] and 9-11 months [n = 13]) showed an average increase of approximately 2 mmHg in COP of 9-month-old to 11-month-old infants, compared with 1-month-old to 3-month-old infants (one-way analysis of variance; P = 0.26). There was no gender difference in the COP level (unpaired t-test), with an average of 25.1 +/- 2.4 mmHg in 19 male infants compared with 25.2 +/- 2.9 in 18 female infants. The 95% confidence interval for COP in both male and female infants (n = 37) was between 24.3 to 26.0 mmHg, ranging from 19.5 to 30.3 mmHg, with a median value of 25.2 mmHg. CONCLUSIONS: The data accept the null hypothesis that the COP range in infants younger than 1 year old is similar to those observed in adult subjects. Our observations, compared with previously reported neonatal COP values, suggest that there is a sharp increase in COP within the first months after birth. (+info)